A Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or without Brain Metastases

About this Study

The study is to compare the good or bad effects of using the experimental drug ABT-888 (Veliparib)  along with cisplatin to using cisplatin alone. The combination of the 2 drugs could shrink your cancer but could also cause side effects. This study will allow researchers to know whether this different approach is better, the same, or worse than the usual approach of chemotherapy.

Sponsor Protocol ID:S1416 
IRB Number:2017-0114
Closed for Enrollment
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Women and minorities
  • Males can be enrolled

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Craft, Barbara S, M.D.
How to participate in our Clinical Trials